Research
Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly improves cardiometabolic risk factors—including waist circumference, HbA1c, blood pressure, and lipid profiles—in adults with overweight or obesity, with or without type 2 diabetes.
If you have obesity or overweight with related health risks, once-weekly semaglutide 2.4 mg, combined with a calorie-reduced diet and regular exercise, significantly improves key health markers like blood pressure, blood sugar, and cholesterol. This treatment is most effective when used long-term, as stopping it can reverse these benefits.
StrongSupportsVERY_HIGH confidence
In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure (SBP), and diastolic blood pressure, as well as positive changes in glycated hemoglobin (HbA1c), C-reactive protein, and lipid levels.
Why this rating
Based on multiple global phase 3 randomized, double-blind, placebo-controlled trials (STEP 1-5).
Source
Cardiometabolic risk factors efficacy of semaglutide in the STEP program
Anastassia Amaro et al. · Postgraduate Medicine · 2022
narrative_review · n=5988Cited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →